Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia September 18, 2024
Engrail closes $157M series B, fueled by investors’ renewed interest in neuropsychiatry March 19, 2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies March 19, 2024
